Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11493904 | 0.88 | SMN1; SMN2 (0.39) | SMN1; SMN2ATMALDH1A1MAPTCES2 | |
| SCHEMBL16675402 | 0.74 | SMN1; SMN2 (0.57) | SMN1; SMN2ATMALDH1A1MAPTCES2 | |
| SCHEMBL13010088 | 0.72 | SMN1; SMN2 (0.44) | SMN1; SMN2ATMALDH1A1MAPTCES2 | |
| SCHEMBL853674 | 0.72 | MAPT (0.52) | SMN1; SMN2ATMALDH1A1MAPTCES2 | |
| SCHEMBL359232 | 0.72 | ATM (0.52) | SMN1; SMN2ATMALDH1A1MAPTCES2 | |
| SCHEMBL22080994 | 0.71 | ALDH1A1 (0.57) | SMN1; SMN2ATMALDH1A1MAPTCES2 | |
| SCHEMBL22080461 | 0.71 | ALDH1A1 (0.57) | SMN1; SMN2ATMALDH1A1MAPTCES2 | |
| Methane SCHEMBL21391655 | 0.70 | ATM (0.50) | SMN1; SMN2ATMALDH1A1MAPTCES2 | |
| SCHEMBL28164197 | 0.70 | ATM (0.50) | SMN1; SMN2ATMALDH1A1MAPTCES2 | |
| SCHEMBL16211065 | 0.70 | SMN1; SMN2 (0.45) | SMN1; SMN2ATMALDH1A1MAPTCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176773-A1 | Non-Peptidic Inhibitors of AKAP/PKA Interaction | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176773-A1 | Non-Peptidic Inhibitors of AKAP/PKA Interaction | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2009-07-09 | — | — | US | disclosed |
| JP-2003146928-A | METHOD FOR DISTILLING OXYSTYRENE DERIVATIVE | HOKKO CHEM IND CO LTD | 2003-05-21 | — | — | JP | disclosed |
| US-4237326-A | SOLUTION OF METHYLATED BENZOQUINONE-4-OXIME | MITSUBISHI PETROCHEMICAL COMPANY LIMITED (JP) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176773-A1 | Non-Peptidic Inhibitors of AKAP/PKA Interaction | PRKCH, AIP, PRKCE | SMN1; SMN2 4491/4885ATM 2047/4885ALDH1A1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.